INT215946

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.10
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 33
Total Number 33
Disease Relevance 8.41
Pain Relevance 1.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Phc1) DNA binding (Phc1)
Anatomy Link Frequency
capsule 7
arm 1
skin 1
Phc1 (Mus musculus)
Pain Link Frequency Relevance Heat
drug abuse 233 88.20 High High
Dopamine 309 83.56 Quite High
depression 281 83.52 Quite High
withdrawal 12 81.48 Quite High
transdermal 54 76.64 Quite High
Clonidine 142 74.88 Quite High
Onset of action 22 73.00 Quite High
Central nervous system 47 64.32 Quite High
cocaine 36 60.32 Quite High
Serotonin 19 50.00 Quite Low
Disease Link Frequency Relevance Heat
Attention Deficit Hyperactivity Disorder 4611 99.32 Very High Very High Very High
Drug Dependence 392 88.20 High High
Attention Deficit And Disruptive Behavior Disorders 3 86.64 High High
Pressure And Volume Under Development 238 84.48 Quite High
Substance Abuse 48 84.20 Quite High
Depression 319 83.52 Quite High
Learning Disorders 1 82.04 Quite High
Spontaneous Abortion 2 71.32 Quite High
Mental Disorders 144 67.36 Quite High
Schizophrenia 1 66.08 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Results from a recent, large randomized, six week, placebocontrolled clinical trial documented that osmotic release methylphenidate (OROS-MPH) at daily average doses of 1 mg/kg/day was also highly effective and well tolerated in the treatment of adults with ADHD [12].
Localization (release) of MPH associated with attention deficit hyperactivity disorder
1) Confidence 0.10 Published 2007 Journal BMC Psychiatry Section Body Doc Link PMC2075491 Disease Relevance 0.45 Pain Relevance 0
Effect of 5-HTTLPR on behavioral response to MPH
Localization (response) of MPH
2) Confidence 0.09 Published 2010 Journal BMC Psychiatry Section Body Doc Link PMC2905344 Disease Relevance 0.37 Pain Relevance 0
This current study design however is potentially more robust given the placebo arm, which acts as an internal control, quantitative measures of MPH response by two raters, namely parents and teachers, as well as consideration of comorbid disorders.
Localization (response) of MPH in arm
3) Confidence 0.09 Published 2010 Journal BMC Psychiatry Section Body Doc Link PMC2905344 Disease Relevance 0.08 Pain Relevance 0
Earlier cost and efficacy studies of drug treatments for ADHD in children and youth indicated no significant differences among treatments; however, immediate-release MPH and extended-release MPH preparations had lower total expected costs.78,79 In a 6-month follow up of 4569 patients receiving 3 alternative drug therapies for ADHD (OROS MPH, extended-release mixed amphetamine salts, atomoxetine), adults treated with OROS MPH had slightly lower medical and total medical and drug costs than those treated with MAS-XR or atomoxetine after adjusting for patient characteristics including substance abuse, depression, and comorbid disorders.
Localization (release) of MPH associated with depression, drug abuse and attention deficit hyperactivity disorder
4) Confidence 0.06 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2732009 Disease Relevance 0.48 Pain Relevance 0.12
Earlier cost and efficacy studies of drug treatments for ADHD in children and youth indicated no significant differences among treatments; however, immediate-release MPH and extended-release MPH preparations had lower total expected costs.78,79 In a 6-month follow up of 4569 patients receiving 3 alternative drug therapies for ADHD (OROS MPH, extended-release mixed amphetamine salts, atomoxetine), adults treated with OROS MPH had slightly lower medical and total medical and drug costs than those treated with MAS-XR or atomoxetine after adjusting for patient characteristics including substance abuse, depression, and comorbid disorders.
Localization (release) of MPH associated with depression, drug abuse and attention deficit hyperactivity disorder
5) Confidence 0.06 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2732009 Disease Relevance 0.48 Pain Relevance 0.12
An MPH patch (Daytrana®) was released in June 2006 and allows effect for up to 12 hours; it is applied in the morning and removed in the afternoon or evening, providing 10 to 30 mg of MPH depending on the patch size used.1,14–16 Approximately half the patients develop some type of skin reaction.
Localization (released) of MPH in skin
6) Confidence 0.04 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695228 Disease Relevance 0.10 Pain Relevance 0
Metadate CDTM is produced as a 20 mg MPH capsule with coated beads that allows immediate release of 30% of the MPH and sustained release of the remaining MPH over 6 to 10 hours.
Localization (release) of MPH in capsule
7) Confidence 0.04 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695228 Disease Relevance 0.07 Pain Relevance 0
Ritalin LA® is an MPH capsule manufactured as a 20 mg, 30 mg, and 40 mg capsule with similar amounts of IR (immediate release) and SR (sustained release) beads that result in release of MPH up to 8 hours as if two IR formulations were taken 4 hours apart.1,14 The recommended practice is to begin with a daily 20 mg capsule and slowly increase if needed to the 40 mg capsule.
Localization (release) of MPH in capsule
8) Confidence 0.04 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695228 Disease Relevance 0.08 Pain Relevance 0
Metadate CDTM is produced as a 20 mg MPH capsule with coated beads that allows immediate release of 30% of the MPH and sustained release of the remaining MPH over 6 to 10 hours.
Localization (release) of MPH in capsule
9) Confidence 0.04 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695228 Disease Relevance 0.07 Pain Relevance 0
It comes as a 20 mg sustained released tablet that results in a release of about 7 mg of short-acting MPH over several hours.
Localization (release) of MPH
10) Confidence 0.03 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695228 Disease Relevance 0.06 Pain Relevance 0.15
Metadate CDTM is produced as a 20 mg MPH capsule with coated beads that allows immediate release of 30% of the MPH and sustained release of the remaining MPH over 6 to 10 hours.
Localization (release) of MPH in capsule
11) Confidence 0.03 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695228 Disease Relevance 0.07 Pain Relevance 0
Concerta® is a sustained release MPH product that uses the OROS mechanism or osmotic release process in which there is a tri-layer core covered by a semi-permeable membrane with a laser-drilled hole on one end.1,14 There is both immediate release of MPH (22%) from the overcoat and then a gradual release of MPH lasting up to 10 to 16 hours.
Localization (release) of MPH
12) Confidence 0.03 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695228 Disease Relevance 0 Pain Relevance 0
The ADHD boys underwent a double-blind, placebo-controlled, cross-over design of placebo or a single 0.5-mg/kg dose (rounded up to the nearest 0.5 mg) of immediate-release MPH delivered in capsules.
Localization (release) of MPH in capsules associated with attention deficit hyperactivity disorder
13) Confidence 0.03 Published 2008 Journal Psychopharmacology (Berl) Section Body Doc Link PMC2704617 Disease Relevance 0.60 Pain Relevance 0
During the last decade, the pharmacotherapeutic options for the treatment of ADHD in the Netherlands have widened by the introduction of extended-release formulations of methylphenidate (MPH ER, Concerta®) in 2003 and the new active molecule atomoxetine (ATX, Strattera®) in 2005.
Localization (release) of MPH associated with attention deficit hyperactivity disorder
14) Confidence 0.01 Published 2010 Journal Atten Defic Hyperact Disord Section Body Doc Link PMC3000908 Disease Relevance 0.77 Pain Relevance 0.07
If long-acting stimulant preparations are used, starting dose for extend released MPH (Concerta) is 18 mg, for the controlled released MPH (Biphentin) is 10 mg, and 5 mg for mixed amphetamine salts XR (Adderall XR).
Localization (released) of MPH
15) Confidence 0.01 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2518387 Disease Relevance 0.20 Pain Relevance 0
If long-acting stimulant preparations are used, starting dose for extend released MPH (Concerta) is 18 mg, for the controlled released MPH (Biphentin) is 10 mg, and 5 mg for mixed amphetamine salts XR (Adderall XR).
Localization (released) of MPH
16) Confidence 0.01 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2515906 Disease Relevance 0.20 Pain Relevance 0
Whereas immediate release MPH can be crushed and parenterally administered as a common way of abuse, the OROS delivery mechanism does not allow the pills to be crushed and injected or inhaled.
Localization (release) of MPH
17) Confidence 0.01 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2518387 Disease Relevance 0.05 Pain Relevance 0.04
OROS methylphenidate (Concerta) is an extended release MPH, that uses an oral osmotic release system (OROS).
Localization (release) of MPH
18) Confidence 0.01 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2515906 Disease Relevance 0.23 Pain Relevance 0
Controlled released MPH is available in seven different dosages, and the capsule can be opened so that the drug may be sprinkled on food.
Localization (released) of MPH in capsule
19) Confidence 0.01 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2515906 Disease Relevance 0.25 Pain Relevance 0.03
If long-acting stimulant preparations are used, starting dose for extend released MPH (Concerta) is 18 mg, for the controlled released MPH (Biphentin) is 10 mg, and 5 mg for mixed amphetamine salts XR (Adderall XR).
Localization (released) of MPH
20) Confidence 0.01 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2515906 Disease Relevance 0.20 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox